Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
Sigilon Therapeutics (NASDAQ:SGTX), a biotech firm focused on functional cures for chronic diseases, announced participation in two healthcare investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sigilon Therapeutics (NASDAQ:SGTX), a biotech firm focused on functional cures for chronic diseases, announced participation in two healthcare investor conferences. CEO Rogerio Vivaldi will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 8:00 AM ET in a live fireside chat. He will also present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET through an on-demand corporate presentation. Webcasts will be available on the company's website.
Details
News Market Reaction – SGTX
The recorded move for SGTX in the trading session of this news was -0.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences.
Presentation Details:
Event: Morgan Stanley 19th Annual Global Healthcare Conference
Date: Friday, September 10, 2021
Time: 8:00 AM ET
Details: Live Fireside Chat
Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: 7:00 AM ET
Details: On Demand Corporate Presentation
Webcasts of the Morgan Stanley fireside chat and the H.C. Wainwright corporate presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at www.sigilon.com. A replay of each webcast will be available at the same location following the event.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Investor Contact
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837
Media Contacts
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349
Brandon Hagen
Manager, Communications
Sigilon Therapeutics
brandon.hagen@sigilon.com
617-586-2851
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.